Clinical Edge Journal Scan

Multimodal imaging of DIP-joint and SEC can help distinguish PsA from psoriasis or OA


 

Key clinical point: Ultrasound (US), magnetic resonance imaging (MRI), and X-ray could differentiate psoriatic arthritis (PsA) from psoriasis and hand osteoarthritis (OA) based on the degree of structural involvement in the distal interphalangeal (DIP)-joint and synovio-entheseal complex (SEC).

Major finding: US-detected new bone formation (NBF; risk ratio [RR] 0.52; P < .001) and DIP-joint synovial hypertrophy (RR 0.66; P = .005) along with PsA MRI scores (all P < .001) were associated with a lower risk for PsA vs. OA. Patients with PsA vs. psoriasis had a higher prevalence of X-ray entheseal change (mean difference 0.42; P = .024) and a higher trend toward US-detected NBF and erosions.

Study details: This prospective, cross-sectional study included 50 patients with DIP-joint PsA and nail involvement, 12 patients with psoriasis and nail involvement, and 13 patients with erosive and nonerosive OA.

Disclosures: The study was funded by Novartis, The Oak Foundation, and others. Some authors declared receiving speaker/consulting fees, research grants, or honoraria or serving as members of advisory board or consultants for several sources.

Source: Guldberg-Møller J et al. Multimodal imaging of the distal interphalangeal-joint synovio-entheseal complex in psoriatic arthritis (MIDAS): A cross-sectional study on the diagnostic accuracy of different imaging modalities comparing psoriatic arthritis to psoriasis and osteoarthritis. RMD Open. 2022;8:e002109 (Mar 28). Doi: 10.1136/rmdopen-2021-002109

Recommended Reading

Slight improvement in axial PsA with DMARD therapy irrespective of HLA-B27 status
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: PsA April 2022
MDedge Rheumatology
Apremilast has neutral effect on vascular inflammation in psoriasis study
MDedge Rheumatology
Hypocaloric diet controls joint activity in psoriatic arthritis – regardless of weight loss
MDedge Rheumatology
IL-17 inhibitors associated with higher treatment persistence in PsA
MDedge Rheumatology
Robust and sustained improvement with guselkumab in a diverse population of patients with PsA
MDedge Rheumatology
PsA: Rapid and sustained improvement in pain with upadacitinib
MDedge Rheumatology
Dermatological improvements translate to enhanced QoL in PsA
MDedge Rheumatology
Differential response to ixekizumab among males and females with PsA
MDedge Rheumatology
Factors associated with increased sleep disturbance in PsA
MDedge Rheumatology